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Abstract
Introduction It has been well documented that the pineal
hormone, melatonin, which plays a major role in the control of
reproduction in mammals, also plays a role in the incidence and
growth of breast and mammary cancer. The curative effect of
melatonin on the growth of dimethylbenz [a]anthracene-induced
(DMBA-induced) mammary adenocarcinoma (ADK) has been
previously well documented in the female Sprague–Dawley rat.
However, the preventive effect of melatonin in limiting the
frequency of cancer initiation has not been well documented.
Methods The aim of this study was to compare the potency of
melatonin to limit the frequency of mammary cancer initiation
with its potency to inhibit tumor progression once initiation, at
55 days of age, was achieved. The present study compared the
effect of preventive treatment with melatonin (10 mg/kg daily)
administered for only 15 days before the administration of
DMBA with the effect of long-term (6-month) curative treatment
with the same dose of melatonin starting the day after DMBA
administration. The rats were followed up for a year after the
administration of the DMBA.
Results The results clearly showed almost identical preventive
and curative effects of melatonin on the growth of DMBA-
induced mammary ADK. Many hypotheses have been proposed
to explain the inhibitory effects of melatonin. However, the
mechanisms responsible for its strong preventive effect are still
a matter of debate. At least, it can be envisaged that the artificial
amplification of the intensity of the circadian rhythm of melatonin
could markedly reduce the DNA damage provoked by DMBA
and therefore the frequency of cancer initiation.
Conclusion In view of the present results, obtained in the female
Sprague–Dawley rat, it can be envisaged that the long-term
inhibition of mammary ADK promotion by a brief, preventive
treatment with melatonin could also reduce the risk of breast
cancer induced in women by unidentified environmental factors.
Introduction
It has been well documented that the pineal hormone, mela-
tonin, besides its well established circadian rhythm, plays a
major role in the control of reproduction in mammals [1,2]. The
role of the pineal gland, the major source of melatonin, in the
development of breast [3] and mammary [4,5] cancer has
been clearly documented. Also, it has been shown that mela-
tonin may exert in vivo [6,7] and in vitro [8-10] an oncostatic
activity by at least a direct action on the mammary tissue [11]
and on the activation of estrogen receptor (ER) for DNA bind-
ing [12], or by modulation of the expression of ER mRNA [13],
or by an increase of the ER binding activity [14]. Recently, it
was shown that melatonin acts as a calmodulin antagonist,
inducing conformational changes in the ERα –calmodulin com-
plex and thus impairing the binding of 17β -estradiol (E2) and
the ERα –calmodulin complex to DNA and therefore prevent-
ing ERα -dependent transcription [15]. Also, 17β -estradiol
treatment of pineal glands in an in vitro perifusion system leads
to complete blunting of the isoproterenol-induced stimulation
of melatonin secretion in 7,12-dimethylbenz [a]anthracene-
treated (DMBA-treated) female Sprague–Dawley rats [16].
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On the other hand, a single intragastric admininistration of
DMBA has been shown to induce mammary tumors in young,
cycling female Sprague–Dawley rats [17]. This carcinogen
interacts with rapidly proliferating cells in the terminal end
buds, forming DNA adducts, which in turn participate in trans-
forming the normal terminal end bud cells to malignant path-
ways [18-20]. The susceptibility of Sprague–Dawley rats to
DMBA is maximal at 55 to 60 days of age and is abolished by
ovariectomy, suggesting the inducible action of the carcino-
gen depends on ovarian secretions [21]. Furthermore, during
the latency period, estrous cycles are associated with blunted
preovulatory surges of luteinizing hormone and follicle-stimu-
lating hormone [22], an increased surge of 17β -estradiol [23],
and disruption of the expression patterns of the genes for
hypothalamic gonadotropin-releasing hormone and its pitui-
tary receptor [24]. Moreover, ovariectomized rats pretreated
with DMBA exhibit blunted release of luteinizing hormone in
response to in vivo estradiol replacement, and reduced
release of gonadotropin-releasing hormone as measured in
vitro using synaptosomes from the mediobasal hypothalamus
[25]
Considering the estrogenic properties of the DMBA molecule
[26], it is possible that the carcinogen exerts its long-lasting
effects at least on the plasma membrane of estrogen-sensitive
neurons [27]. In addition, DMBA can interact with the ER and
partially mimic both the positive and negative feedback actions
of estradiol in ovariectomized rats [28].
The aim of this study was to compare the potency of melatonin
to limit the frequency of cancer initiation with its potency to
inhibit tumor progression once initiation by DMBA was
achieved.
Our research team has previously shown that the administra-
tion of melatonin (10 mg/kg daily) for 6 months markedly
reduces the percentage of tumor-bearing animals in DMBA-
treated female rats, by 65% [16].
This study compared, over 1 year, the effect of preventive
treatment with melatonin (10 mg/kg daily), administered for
only 15 days before the administration of DMBA, to the effect
of a curative treatment with the same dose of melatonin admin-
istered for 6 months after the administration of DMBA.
Materials and methods
Animals
Sixty 40-day-old female Sprague–Dawley rats (Charles River,
L'Arbresle, France), 40 days of age, were used. They were
housed (five animals per cage) under conditions of controlled
temperature (20 to 22°C) and light (12 hours light /12 hours
darkness; lights on from 0700 to 1900 hours). The animals
had free access to commercial pelleted rat food (UAR, Villem-
oisson, Epinay-sur-Orge, France) and water. After 5 days of
acclimatization, they were randomly assigned to three experi-
mental groups of 20 animals each.
The first group of animals received a daily intragastric admin-
istration (in 1 ml of hydroxyethylcellulose at 1%) of melatonin
(10 mg/kg daily, given no more than 3 hours before lights were
turned off) for 15 days (from 45 to 59 days of age). At age 60
days, at noon on the day after cessation of the treatment, they
were given a single intragastric administration of DMBA
(Sigma, Saint Quentin Fallavier, France) (75 mg/kg) diluted in
1 ml of sesame oil, as described elsewhere [17].
The second group of animals received a single intragastric
administration of DMBA (75 mg/kg) at noon when they were
55 days old. Then, beginning the next day, they received a
daily intragastric administration of melatonin (10 mg/kg daily,
given no more than 3 hours before the lights were turned off)
for 6 months.
The third group of animals was given a single intragastric
administration of DMBA (75 mg/kg, given at noon) at 55 days
of age.
All the animals were followed up for 12 months after the
administration of DMBA.
The occurrence of palpable mammary tumors was recorded
every 2 weeks after the intragastric administration of DMBA.
Tumor histology
The number and the size of mammary tumors were recorded
and a histological analysis was performed. Tumors were
removed when the largest diameter was at least 2 cm. They
were dissected, trimmed free of surrounding connective tis-
sue, and placed in 37% formaldehyde. Tumors were fixed in
paraffin wax, sectioned, and stained with hematoxylin and
eosin. Sections were examined by one of us (AM).
The lesions observed from the removed samples ranged
widely from benign to malignant, with pathology closely resem-
bling that seen in human breast tumors. The observed tumors
were generally classified as adenocarcinomas (ADKs), with
marked nuclear irregularities and numerous mitoses. Only
clearly characterized ADKs were taken into account in the
results presented in this study.
Statistical analysis
The normality of data was analyzed with the Kolmogorov–
Smirnov and Shapiro–Wilk tests.
As a preliminary step in the statistical process, a two-factor
analysis of variance was performed: it was based on the com-
parison of means weighted by the time factor, because the
classical underlying assumptions did not hold.Available online http://breast-cancer-research.com/content/7/4/R470
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Because the samples were not drawn from gaussian popula-
tions, Student's t and the Welsh tests could not be used;
therefore, the Mann–Whitney test was applied.
The percentages of animals diagnosed with mammary ADK in
each data set were compared using the Fisher exact test (one-
sided P-values).
Results
ANOVA two-way analysis
There was strong evidence (P < 0.01) that the ADK number
increases within months after DMBA and that there was a very
strong decrease of the number of ADK in treated rat groups (P
= 0.01). In order to analyse these differences more closely, we
looked to see whether the various time groups differed,
whether any such difference was due to a decrease in the
number of ADK-bearing animals, and whether the ADK
number per ADK-bearing animals was reduced.
Comparison of the mean numbers of mammary ADKs 
between the groups
In control animals, there was an almost linear increase in the
mean number of ADKs between the second and ninth months
after DMBA administration (Fig. 1). The highest number (3.05
± 0.59) was found 9 months after the administration of DMBA.
In the melatonin-treated rats, there was a significant reduction
of the number of ADKs in both the group given preventive
treatment and that given curative treatment (Mann–Whitney
test). Although the test used is nonparametric, the sample sta-
tistics mean and standard error of the mean are shown in Fig.
1 for a better description of the groups.
Twelve months after DMBA administration, values were 1.30
± 0.30 in the the group given preventive treatment and 0.95 ±
0.23 in the group given curative treatment, vs 3.05 ± 0.59 in
the control group (Fig. 1). Also, there was no statistical differ-
ence between the preventively and curatively treated groups
(1.30 ± 0.30 vs 0.95 ± 0.23) (Mann–Whitney test). Neverthe-
less, the curative group differed more significantly from the
control group than the preventive group (0.002 <P < 0.01),
from 6 to 10 months.
Percentage of rats with at least one palpable mammary 
ADK
In control animals, the first palpable mammary ADK (latency
period) appeared 2 months after DMBA administration (Fig.
2). By 6 months after the administration of DMBA, 75% of con-
trol rats exhibited at least one palpable mammary ADK.
In animals that were pretreated daily with melatonin for either
15 days before the administration of DMBA or for 6 months
after the administration of DMBA, there was a marked reduc-
tion in the percentage of animals with mammary ADKs as com-
pared with the control group. Six months after DMBA
administration, the ADK rate was 43% in the group given pre-
ventive treatment (P = 0.04 vs control group) and 35% in the
group given curative treatment (P = 0.01 vs control group), vs
75% in the control group. The difference between the rates in
the two experimental groups was not statistically significant.
However, the inhibitory effect last significantly longer in the
group given preventive treatment than in that given curative
treatment (10 months vs 7 months, respectively).
Figure 1
Average number (mean ± standard error of the mean) of mammary adenocarcinomas (ADKs) per rat after daily administration of melatonin (10 mg/ kg) for either 15 days before (preventive treatment; open diamonds) or 6 months after (curative treatment; filled diamonds) the administration of  dimethylbenz [a]anthracene (DMBA) Average number (mean ± standard error of the mean) of mammary adenocarcinomas (ADKs) per rat after daily administration of melatonin (10 mg/
kg) for either 15 days before (preventive treatment; open diamonds) or 6 months after (curative treatment; filled diamonds) the administration of 
dimethylbenz [a]anthracene (DMBA). In both cases, the rats were followed up for 12 months after the administration of DMBA. Hatched bar, dura-
tion of preventive treatment; filled bar, duration of curative treatment. *P < 0.05 vs controls; **P < 0.01 vs controls.
Control
Preventive
Curative
Time after DMBA administration
* *
*
* *
** ** * ** *
* *
* *
*
**
*
*
4
3
2
1
0
A
v
e
r
a
g
e
n
u
m
b
e
r
(
+
S
E
M
)
o
f
A
D
K
p
e
r
r
a
t
12 11 10 9 8 7 6 5 4 3 2 1 0Breast Cancer Research    Vol 7 No 4    Lenoir et al.
R473
Comparison of the mean number of mammary ADK 
number between groups of ADK-bearing animals  (Fig. 3)
In control animals, between the fifth and the ninth month after
DMBA administration there was an almost linear increase in
the mean number of ADKs per ADK-bearing animal. At 9
months after administration of DMBA, the mean number (±
standard error of the mean) was 4 ± 0.6 ADKs per ADK-bear-
ing animal.
In the melatonin-treated female rats given preventive treat-
ment, there was a reduction in the mean number of ADK per
ADK-bearing animal but it did not reach a high degree of sta-
tistical significance.
The number of ADKs in the melatonin-treated female rats given
curative treatment (1.38 ± 0.18 at 9 months after DMBA
administration and 1.58 ± 0.26 at 12 months after DMBA
administration) was significantly lower than in the control
group (4 ± 0.59) (0.02 <P < 0.05 for month 7 to month 11
and 0.01 <P < 0.02 for month 12).
The differences between the preventive and the curative group
(P > 0.1) and between the control and the preventive group (P
≥  0.05) were not statistically significant. However, the differ-
ence between the control and the preventive group was close
or equal to 0.05 from month 7 to month 12.
Discussion
The aim of this study was to compare the effect of daily intra-
gastric administration of melatonin for 15 days before the
administration of DMBA in the female rat with the effect of
such treatment for 6 months after the administration of DMBA.
Our results clearly show the preventive and curative effects of
melatonin on the growth of DMBA-induced mammary ADK.
The curative effect of melatonin on the growth of DMBA-
induced mammary ADK in the female rat has been previously
well documented [4,5,16]. In the present study, the maximal
inhibitory effect of melatonin on the percentage of rats with
mammary ADK was by 62% at 4 months and 68% after 6
months of treatment (at the end of treatment). After the end of
treatment, the intensity of the inhibitory effect started to
decrease, but it was still significant up to 4 months after the
end of treatment (10 months after DMBA administration).
The preventive (protective) effect of a brief period of melatonin
treatment before DMBA administration has not been docu-
mented under the same experimental conditions. The maximal
inhibitory effect of melatonin on the percentage of female rats
with mammary ADK was a reduction to 62% relative to con-
trols, at 4 months after DMBA administration. The Inhibition
was significant up to 7 months after DMBA administration, but
not later. Very similar results were obtained when the mean
number of ADKs per rat or the mean number of ADKs per
ADK-bearing rat were considered. Regarding the mean
number of ADKs per ADK-bearing rat, there was a loss of sig-
nificance, but there was no statistical difference between the
effect of the preventive treatment and the curative treatment.
Figure 2
Incidence of mammary adenocarcinomas (ADKs) after daily administration of melatonin (10 mg/kg) for either 15 days before (preventive treatment;  open diamonds) or 6 months after (curative treatment; filled diamonds) the administration of dimethylbenz [a]anthracene (DMBA) Incidence of mammary adenocarcinomas (ADKs) after daily administration of melatonin (10 mg/kg) for either 15 days before (preventive treatment; 
open diamonds) or 6 months after (curative treatment; filled diamonds) the administration of dimethylbenz [a]anthracene (DMBA). In both cases, the 
rats were followed up for 12 months after the administration of DMBA. Hatched bar, duration of preventive treatment; filled bar, duration of curative 
treatment. *P < 0.05 vs controls; **P < 0.01 vs controls.
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Interestingly enough, there was no statistical difference
between the oncostatic activity afforded by melatonin accord-
ing to whether it was administered by the preventive or the cur-
ative protocol: the incidence and number of ADKs were very
similar, up to 7 months after DMBA administration. A major
finding of this study is that 7 months after the induction of the
carcinogenic process, both the percentage of animals with
ADK and the mean number of ADKs per animal were still
reduced in animals treated with melatonin for 15 days before
DMBA administration.
In this study, the preventive treatment consisted of only 15
days of treatment, for technical reasons: the treatment could
not be started before the rats were 40 days old, to avoid inter-
ference with the onset of estral cycling. A longer period of pre-
treatment with melatonin before the administration of DMBA
might have led to a more pronounced inhibitory effect on the
growth of DMBA-induced mammary ADK.
Many hypotheses have been proposed to explain the inhibitory
effects of melatonin. They include modulation of the reproduc-
tive neuroendocrine axis (down-regulation of the gonadotropic
axis and decrease of estrogen and prolactin levels); immu-
noenhancing activity; antioxidative properties; and direct anti-
tumorigenic activity [8,9,29-32]. The direct oncostatic effect
of metatonin has been mostly studied on in vitro models of
estrogen-responsive breast cancer. In MCF-7 cells, melatonin
interferes with the estrogen response pathway through the
suppression of ERα  expression and transactivation to affect
the level of growth regulatory genes mediating the mitogenic
action of estradiol [33,34]. Also, melatonin inhibits EGF and
MAPK-induced cell proliferation via the suppression of linoleic
acid uptake and metabolism [35] and it promotes cell differen-
tiation (differentiation of terminal end buds) by reducing the
invasiveness of MCF-7 cells and increasing gap functional
contacts [35]
It is thought that DMBA acts, at the mammary gland level,
throughout the formation of a cascade of metabolites (gener-
ated at least in the liver and the mammary gland) which ends
with its ultimate carcinogenic form, the 3,4-dihydro-diol-1,2-
epoxide, before adduct formation with DNA occurs [36,37].
Melatonin may inhibit adduct formation with DNA because of
its free radical scavenging/antioxidant action [38]. In that view,
it may be envisaged that the strong artificial amplification of the
intensity of the circadian rhythm of melatonin, provoked by an
exogenous supply, before the administration of DMBA could
play a major preventive role against the induction of the carci-
nogenic process [39].
In the group of rats given long-term melatonin treatment begin-
ning a day after DMBA administration, DMBA metabolism and
adduct formation certainly still occur for at least 5 days
(unpublished results). Therefore, the results obtained in the
curative group represent the sum of an inhibition of both the
initiation and the promotion process. Obviously, if the mela-
tonin treatment had started a week or two after DMBA admin-
istration, we might have seen different results. However, in
another carcinogen model of mammary tumorigenesis – the N-
nitrosomethylurea model of hormone-responsive rat mammary
carcinogenesis – melatonin was without effect on carcinogen-
esis when its administration was restricted to the initiation
Figure 3
Average number (mean ± standard error of the mean) of mammary adenocarcinomas (ADKs) per ADK-bearing rat after daily administration of mela- tonin (10 mg/kg) for either 15 days before (preventive treatment; open diamonds) or 6 months after (curative treatment; filled diamonds) the admin- istration of dimethylbenz [a]anthracene (DMBA) Average number (mean ± standard error of the mean) of mammary adenocarcinomas (ADKs) per ADK-bearing rat after daily administration of mela-
tonin (10 mg/kg) for either 15 days before (preventive treatment; open diamonds) or 6 months after (curative treatment; filled diamonds) the admin-
istration of dimethylbenz [a]anthracene (DMBA). In both cases, the rats were followed up for 12 months after the administration of DMBA. Hatched 
bar, duration of preventive treatment; filled bar, duration of curative treatment. *P < 0.05 vs controls; **P < 0.01 vs controls.
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phase but was quite effective during the promotion phase
[40].
Also, changes in circadian rhythms have already been docu-
mented to be associated with carcinogenesis [41,42], and it
has been shown that the administration of melatonin could
restore the deficiency of the circadian clock provoked by the
low secretion of melatonin induced by DMBA [16]. Therefore,
it can be envisaged that amplifying the intensity of the circa-
dian rhythm of melatonin might help to prevent the induction of
the carcinogenic process by DMBA.
Conclusion
In view of the present results obtained in the female Sprague–
Dawley rat and of the well-documented oncostatic properties
of melatonin, it can be envisaged that the long-term inhibition
of mammary ADK promotion by a brief preventive treatment
with melatonin could also reduce the risk of breast cancer
induced in women by unidentified environmental factors.
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